drugset / Trial / NCT04176952
PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer
Phase 2
Terminated
31 enrolled
Judith Dixon-Hughes
NHS Greater Glasgow and Clyde · collabUniversity of Glasgow · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
PRIMUS 002 is looking at 2 different chemotherapy regimens in the neo-adjuvant setting for pancreatic cancer. Each treatment will be given for 3 months prior to surgery
Timeline
- Start
- 2019-03-05
- Primary completion
- 2021-08-19
- Completion
- 2021-08-19
Outcome
Outcome not reported
Stopped (Business): “Due to funding being withdrawn”
Publications
- Dreyer SB, Bryce A, Froeling F, Jackson S, Santana L, Dickson EJ, Coats M, McKay C, Holroyd D, Biankin AV, Jamieson NB, Chang DK. Clinical and molecular landscape of surgically resected early onset pancreatic cancer. Br J Surg. 2026 May 7;113(5):znag032. doi: 10.1093/bjs/znag032.
- Saha A, Wadsley J, Sirohi B, Goody R, Anthony A, Perumal K, Ulahanan D, Collinson F. Can Concurrent Chemoradiotherapy Add Meaningful Benefit in Addition to Induction Chemotherapy in the Management of Borderline Resectable and Locally Advanced Pancreatic Cancer?: A Systematic Review. Pancreas. 2023 Jan 1;52(1):e7-e20. doi: 10.1097/MPA.0000000000002215.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Leucovorin | Small molecule | 350 mg | Intravenous |
| Subject | Nab-paclitaxel | Small molecule | 125 mg/m2 | Intravenous |
| Subject | Nab-paclitaxel | Small molecule | 150 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 1200 mg/m2 | Intravenous |